IMPORTANCE Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma.
A mong patients with persistent asthma that remains suboptimally controlled with the use of inhaled corticosteroids, US guidelines suggest a stepwise approach to modifying therapy that includes increasing the dose of inhaled corticosteroids or adding adjunctive therapies. 1 Inhaled long-acting β-agonists (LABAs) are the preferred adjunctive therapy for patients aged 12 years or older and are considered 1 of several potential adjunctive therapies for patients aged 5 to 11 years. When inhaled corticosteroids and LABA are used as controller therapies, the doses are scheduled on a daily basis and the patient continues to use short-acting β-agonists (SABAs) for as-needed quick relief of symptoms (Box). Given the fast onset of action with the LABA formoterol, 2 it has been hypothesized that the combined use of inhaled corticosteroids and formoterol as needed instead of SABAs would provide quick symptom relief and also deliver steroid sooner during the course of symptom deterioration, thereby effectively managing asthma symptoms and reducing exacerbation risk.
The use of a combination of inhaled corticosteroids and LABA inhaler as both the controller and quick relief therapy is a strategy that has been termed single inhaler therapy or single maintenance and reliever therapy (SMART) and is recommended for asthma management by international guidelines. [3] [4] [5] However, currently there are no combinations of inhaled corticosteroids and LABA approved for combined controller and quick relief therapy in the United States. The objective of this review was to systematically identify and analyze data from trials that compared use of SMART among patients with persistent asthma vs inhaled corticosteroids with or without a LABA used as controller therapy and SABAs as reliever therapy among patients aged 5 years or older.
Methods
A standard protocol was developed and followed and can be found online in its entirety. 6 This article represents 1 of 6 research questions posed in the protocol. Two questions examined the effect of intermittent inhaled corticosteroids among children with recurrent wheezing or among children and adults with persistent asthma and 3 questions evaluated the comparative effectiveness of long-acting muscarinic antagonists vs standard inhaled controllers among patients with uncontrolled and persistent asthma. The final full report addressing all 6 research questions is available on the Agency for Healthcare Research and Quality website. 7 
Data Sources and Searches
We searched MEDLINE via OVID (including in-process and other nonindexed citations), EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews via OVID from database inception through August 2016 and updated through November 28, 2017 ( Figure 1 and eAppendix 1 in the Supplement). The bibliographic database searches were supplemented with backward-citation tracking of relevant publications.
Additional searches included ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform for ongoing studies and those completed with reported results. The scientific resource center of the Agency for Healthcare Research and Quality also requested data from manufacturers.
Study Selection
Studies were included that evaluated patients aged 5 years or older with persistent asthma and compared SMART vs either inhaled corticosteroids alone or inhaled corticosteroids with LABA as the sole controller therapy and used SABA for reliever therapy. We required studies to assess 1 of the following outcomes: asthma exacerbations (systemic use of corticosteroids, hospitalization, emergency department [ED] visits, intensive care admission or intubation, or as defined by the study); all-cause or asthma-specific mortality; spirometry reported as peak, trough, or area under the curve; forced
Box. Key Definitions

Inhaled Corticosteroids
The prescribed use of inhaled corticosteroids is not the same on a daily basis. As prescribed, intermittent dosing of inhaled corticosteroids may specify variations in the dose or frequency of administration. The determinant of intermittent dosing of inhaled corticosteroids may be the patient's decision based on need, an index of worsening asthma, or some other predefined criteria.
expiratory volume in the first second of expiration (FEV 1 ); forced vital capacity (FVC); ratio of FEV 1 to FVC; asthma control assessed by the Asthma Control Test or the 5-item Asthma Control Questionnaire (ACQ-5); asthma-related quality of life assessed by the Asthma Quality of Life Questionnaire; and health care use (additional medication use, additional health care use related to the intervention). A patient response was defined as a reduction in the ACQ-5 score by 0.5 points or greater. 8 A minimally important difference in FEV 1 was defined as a change of 0.2 L. 9 Studies considered for inclusion were randomized clinical trials (RCTs) (parallel or crossover design), prospective or retrospective observational cohort studies, and case-control studies. Crossover trials were included if the outcomes measured after the first treatment period were available and if the washout period was a minimum of 6 weeks for inhaled corticosteroids and 4 weeks for LABA. We did not apply restrictions in publication language or date.
Four independent investigators (D.M.S., E.R.W., E.N., W.L.B.) screened titles and abstracts to determine if the citation met eligibility criteria. Full-text publication review occurred when 2 of the reviewers agreed that a citation met the eligibility criteria. Disagreements were resolved through consensus in consultation with a third reviewer (D.M.S.). We contacted corresponding authors for clarification when needed to assess the inclusion criteria. Abstracts and meeting presentations were matched to their corresponding full-text publication and reviewed for supplemental data.
Data Extraction and Risk of Bias Assessment
One investigator (E.R.W. or E.N.) abstracted data into standardized collection forms and created tables for the evidence and outcomes. A second investigator (E.R.W. or E.N.) verified entries. For crossover trials, data from period 1 were abstracted when available, otherwise we contacted authors for period 1 outcomes.
Two independent reviewers (D.M.S., E.R.W., E.N., or W.L.B.) assessed risk of bias using the Cochrane Collaboration risk of bias tool 10 for RCTs. The individual domains included
(1) random-sequence generation, (2) allocation sequence concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) completeness of outcome data, (6) selective reporting, and (7) 
Data Synthesis and Analysis
Data synthesis was based on pharmacological class rather than an individual drug. Studies were categorized as follows based on the comparator studied and in each case included a SABA reliever: inhaled corticosteroids alone as the controller therapy, both inhaled corticosteroids and LABA as the controller therapy, or either inhaled corticosteroids alone or inhaled corticosteroids and LABA together as the controller therapy. Studies were grouped and analyzed separately based on whether the estimated daily dose of inhaled corticosteroids 1 in the comparator group was the same, higher, or lower than the intervention group. Some studies met criteria for more than 1 of these groups when multiple groups were reported. This article reports the results of SMART vs inhaled corticosteroids with or without a LABA at the same or higher dose of inhaled corticosteroids. The results of SMART vs a control group that allowed both inhaled corticosteroids alone or inhaled corticosteroids and LABA together as the controller therapy, or a lower comparative dose of inhaled corticosteroids appear in the full report.
7
Data synthesis also was based on age categories consistent with the previously used age cut points of 5 to 11 years and 12 years or older. 1 Studies that fit into more than 1 predefined age category were included in the main analysis if they were the only source of data. These studies were added to the age category consistent with the reported mean or median age of the study as a sensitivity analysis. If a study fit into more than 1 age category and reported results separately for the different age subgroups, those subgroups were considered for the main analyses. All analyses were performed using the meta package in R (version 3.4.3; R Project for Statistical Computing). We conducted a meta-analysis of the RCTs using the Hartung-Knapp 11,12 random-effects model to estimate risk ratio (RR) and risk difference with corresponding 95% CIs for binary outcomes and mean difference with corresponding 95% CIs for continuous outcomes. For binary outcomes with rare events (<5%), odds ratios and 95% CIs were calculated using the method of Peto in place of an RR. 13 Because of debate regarding the routine use of the Hartung-Knapp method, 14 recommendations suggest conducting standard random-effects analyses as a sensitivity analysis. 15 Therefore, we reanalyzed each end point using the DerSimonian and Laird random-effects model to determine if any of the conclusions were sensitive to model choice. Additional sensitivity analyses were performed whereby studies considered to have at least 1 of 7 domains rated with high risk of bias (eg, those that did not blind participants or personnel) were removed and the analyses were rerun. The presence of statistical heterogeneity was assessed using the Cochrane P value (P < .10 was considered significant) and the degree of heterogeneity was assessed using the I 2 statistic and a value greater than 50% was considered substantial. 16 We planned to assess publication bias using funnel plot inspection and tests of plot asymmetry when 10 or more trials were pooled. 17 However, none of the pooled analyses reached this threshold. b Meta-analyses were performed when 3 or more studies reported on the same outcome. When data were available for 2 or fewer studies, the results from each study are individually shown. Thus, the groups are treated as a separate comparison with individual results shown.
Strength of Evidence
Risk of Bias
c Outcome data are expressed as mean (SD) or No. of patients with an event. The mean outcome values represent the mean change from baseline for each study group. The mean difference represents the between-group difference in change from baseline.
d The control group used a short-acting β-agonist as the reliever therapy.
e Indicates between-group risk (SMART group minus control group).
f Based on domains of risk of bias, consistency, directness, precision, and publication bias. Additional information appears in eAppendix 2 in the Supplement. Some rows do not have an evidence rating because ratings were given for each outcome as a whole rather than for the individual studies.
g Patient self-administered tool for assessing overall asthma control; range, 5 (worse) to 25 (better control). The minimally important difference is a 3-point change.
36 h Patient self-administered tool for assessing overall asthma control; range, 0 (worse) to 6 (better control). The minimally important difference is a 0.5-point change. Abbreviations: ED, emergency department; LABA, long-acting β-agonist; PEF, peak expiratory flow; SMART, single maintenance and reliever therapy.
a The median age of patients was 8 (range, 4-11) years and 69 (31%) were female.
b The control group used a short-acting β-agonist as the reliever therapy.
c Indicates between-group risk (SMART group minus control group).
d Based on domains of risk of bias, consistency, directness, precision, and publication bias. Additional information appears in eAppendix 2 in the Supplement.
Use of Inhaled Corticosteroids and Long-Acting β-Agonists for Asthma Exacerbations
Original Investigation Research No significant association of SMART with asthma symptom control measured by the ACQ-5 was seen compared with the same dose of inhaled corticosteroids and LABA controller therapy (eFigure 6 in the Supplement) or with a higher dose of inhaled corticosteroids (Table 1) . However, in a single trial, Test for overall effect: t 2 = -4.71, P =.04
Heterogeneity: I 2 = 0%, P = .64
The box sizes are proportional to study weight and the horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range, 0%-100%), and the P value for heterogeneity is a test of heterogeneity across all studies (P <. 10 indicates likely variation across pooled estimates related to statistical heterogeneity). ED indicates emergency department; LABA, long-acting β-agonist; SMART, single maintenance and reliever therapy. Test for overall effect: t 4 = -6.44, P <.001
Heterogeneity: I 2 = 29%, P = .23
The box sizes are proportional to study weight and the horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range, 0%-100%), and the P value for heterogeneity is a test of heterogeneity across all studies (P <. 10 indicates likely variation across pooled estimates related to statistical heterogeneity). ED indicates emergency department; LABA, long-acting β-agonist; SMART, single maintenance and reliever therapy.
Research Original Investigation
Use of Inhaled Corticosteroids and Long-Acting β-Agonists for Asthma Exacerbations (Table 1 and eFigure 7 in the Supplement) vs inhaled corticosteroids and LABA controller therapy at either the same or a higher dose of inhaled corticosteroids. Two trials evaluated asthmarelated quality of life using the Asthma Quality of Life Questionnaire and found no significant association with SMART vs a higher dose of inhaled corticosteroids and LABA controller therapy (Table 1) . SMART was not associated with lower use of rescue medication as inhalations per day vs either the same or a higher dose of inhaled corticosteroids and LABA controller therapy (Table 1 and eFigure 8 in the Supplement).
Among patients aged 4 to 11 years, a subgroup analysis from a single RCT reported that SMART was associated with a lower risk of asthma exacerbations using 3 different composite definitions vs the same dose of inhaled corticosteroids alone as the controller therapy (Table 2) .
Sensitivity Analysis
The results of the sensitivity analyses, whereby all outcomes were reanalyzed using different methods appear in eTable 5 in the Supplement. Three analyses were shown to be sensitive to model choice and the 95% CIs were more narrow than the basecase analysis, resulting in statistically significant findings.
When analyzed using the DerSimonian-Laird randomeffects model and compared with the same dose of inhaled corticosteroids and LABA controller therapy, SMART was associated with a significant improvement in mild asthma exacerbations (RR, 0. When the studies rated as having a high risk of bias were removed during the sensitivity analyses, the overall findings remained consistent (eTable 6 in the Supplement).
Discussion
This systematic review supports the combined use of inhaled corticosteroids and LABA as both the controller and quick relief therapy (SMART) among patients aged 12 years or older compared with using either the same or a higher dose of inhaled corticosteroids alone as the controller therapy or the same or a higher dose of inhaled corticosteroids and LABA as the controller therapy with SABA as the quick relief therapy for patients aged 12 years or older with persistent asthma. Current evidence regarding children aged 4 to 11 years is limited but also suggests similar efficacy associated with SMART.
Persistent asthma severity was not usually defined further in the studies; however, all of the studies required patients to be taking inhaled corticosteroids prior to enrollment and many patients also were taking an LABA. Based on reported mean doses of inhaled corticosteroids prior to enrollment, most patients were taking medium to high doses of inhaled corticosteroids and thus represent patients with asthma severity that is worse than mild persistent asthma.
Efficacy associated with SMART among patients aged 12 years or older is primarily based on a composite outcome including asthma exacerbations requiring systemic corticosteroids, hospitalization, or ED visits. SMART was associated with reduced RRs regardless of the comparator. Although it is recommended that trials report the individual components of a composite outcome, 39 this was rarely done. Some insight is provided from the comparison of SMART vs the same dose of inhaled corticosteroids and LABA controller therapy for which SMART was associated with a reduced risk in a similar magnitude for each of the 3 components of the composite outcome.
Other outcomes including all-cause mortality were rare and there were no asthma-specific deaths among the patients studied. Trials typically lasted 6 to 12 months and thus may be limited in the analysis of such long-term outcomes. Several postmarketing trials mandated by the US Food and Drug Administration that were designed to evaluate the safety of LABA used in combination with inhaled corticosteroids in patients with asthma, albeit traditional dosing not SMART, have not detected any concern regarding serious asthma-related events. [40] [41] [42] This has recently prompted the Food and Drug Administration to remove the black box warning regarding asthma-related deaths from all medications that contain both inhaled corticosteroids and LABA. 43 Current guidelines recommend that asthma management goals not only include risk reduction of asthma exacerbations but also improvement in asthma control. 1 Among patients aged 12 years or older, measures of asthma control were much less frequently available for analysis. Spirometry was represented mostly by FEV 1 . Even though SMART was associated with significantly increased FEV 1 compared with the same comparative dose of inhaled corticosteroids, the difference did not reach the minimally important difference of 0.2 L. 9 Continuous composite measures of asthma symptom control (eg, Asthma Control Test and the ACQ-5) did not support improvement in asthma symptom control with SMART more often than not despite a single trial that found SMART was associated with increased chances of having a response on the ACQ-5 (achievement of a minimally important difference of 0.5).
38,44-46
There are several hypotheses regarding why changes in symptom control were negligible in this review. Based on a systematic review of the literature, some have concluded that a within-patient minimally important difference of 0.5 for the ACQ-5 score is not achievable in studies when controller therapies are added to inhaled corticosteroids. 38 Bateman et al 38 noted that the development of the ACQ-5 was largely based on a population of patients that had not taken steroids or were taking inhaled corticosteroids alone, and initial derivation of the questionnaire was based on physician-perceived improvement in patient symptoms. SMART delivers a fast-acting LABA; therefore, it is reasonable to expect patients to obtain symptom relief in place of a SABA. However, unlike traditional dosing of inhaled corticosteroids and LABA, SMART delivers inhaled corticosteroids sooner during symptom deterioration, which may in part have a role in improvement of other outcomes such as asthma exacerbations. Despite the lack of symptom control found in this review, a retrospective analysis of 5 trials included in this review found that ACQ-5 scores continued to improve over 6 to 12 months of therapy during the trials, regardless of the treatment group. 46 The rates of controlled asthma according to various ACQ-5 cut points also were similar regardless of intervention group and continued to improve over the course of the trials. 46 The data support improved asthma control as measured through validated composite scores with SMART. SMART was not associated with changes in asthmarelated quality of life; however, this outcome was rarely reported and should be a target for future studies evaluating this intervention. In addition, no significant association between SMART and changes in the need for rescue medication inhalations was seen across the various comparators in this review, and only favored SMART vs a higher dose of inhaled corticosteroids alone as the controller therapy, albeit not reaching the minimally important difference of 0.8 inhalations per day. 9 Composite asthma exacerbations were the only outcomes available for analysis among patients aged 4 to 11 years based on data from a subgroup analysis of a single trial.
20,31
Even though a composite outcome for asthma exacerbations was used, it was broader than the literature base for patients aged 12 years or older and included asthma exacerbations requiring systemic steroids, hospitalization, ED visit, a change in PEF to less than 70%, or an increase in inhaled corticosteroids or other asthma medications.
Although lung function can document reduced airflow associated with asthma exacerbations, PEF is less sensitive than FEV 1 . 39 Furthermore, not all reductions in PEF will result in medical intervention as was found in the 1 trial 20 in which 87% of the asthma exacerbations meeting the PEF criterion were retrospectively found not to lead to medical intervention. When the PEF component of the composite outcome was removed, a significant association in favor of SMART was still found; however, the criterion of an increase in inhaled corticosteroids or other medication remained.
20
Even in younger children, this characteristic is not 1 of the recommended definitions of asthma exacerbations.
39
Taken together, the strength of evidence for asthma exacerbation outcomes among patients aged 4 to 11 years was low and more limited than the evidence in support of SMART among patients aged 12 years or older. Future research is needed to confirm the similar efficacy of SMART seen in the prior trial on asthma exacerbations as well as to evaluate other important outcomes such as asthma control and quality of life.
Applicability
The target population for this review included patients aged 5 years or older with persistent asthma. Consistent with the National Asthma Education and Prevention Program's Expert Panel Report 3 guidelines, this systematic review aimed to evaluate patients aged 5 years or older and separately analyzed patients aged 4 to 11 years and aged 12 years or older. The evidence base for patients aged 4 to 11 years was limited to a single subgroup analysis (n = 341) from a single trial and included patients as young as 4 years of age with uncontrolled asthma while receiving inhaled corticosteroids alone.
However, even though this study was the only source of evidence for this age group, the data were included because the mean age was within the target range. Several of the trials fitting the age category of 12 years or older involved mainly older patients (mean ages in the 40s) and thus reflect adult populations rather than adolescents. The majority of trials required patients to either have uncontrolled asthma or required use of rescue SABA during the run-in period. Although SABA use is 1 criterion to measure impairment associated with asthma control, others such as nighttime awakenings, spirometry, and interference with activities of daily living are also suggested.
All but 1 trial evaluated the combination of inhaled corticosteroids and LABA as budesonide and formoterol delivered as a dry-powder inhaler; therefore, the results of this systematic review are most reflective of this particular inhaler. Combination budesonide and formoterol is only available in the United States as a metered-dose inhaler. Data suggest that budesonide and formoterol delivered via a metered-dose inhaler is therapeutically equivalent to the dry-powder inhaler based on morning PEF measured in patients aged 12 years or older with suboptimal asthma control while using inhaled corticosteroids alone. 47 However, specific trials evaluating the metered-dose inhaler in SMART were not available.
Limitations
This study has several limitations. First, this review did not evaluate adverse events associated with administering SMART because it was not within the scope of the review. However, when selecting appropriate therapy for patients, decision makers should consider known harms and costs of these drug therapies. Second, although there were many subgroups of interest, individual analyses could not be conducted due to the lack of reported data, which limits the ability of decision makers to further individualize recommendations. Third, some trials included in this review were determined to have medium risk of bias specifically due to the open-label nature of the study design. Fourth, due to the number of outcomes that were evaluated, some statistically significant associations may represent type I error.
Fifth, there is still debate surrounding the most appropriate statistical model to use within meta-analyses. Due to its more favorable handling of between-study heterogeneity, an a priori decision was made to use a random-effects model with a Hartung-Knapp estimator. 48 However, the HartungKnapp estimator has received criticism and some recommend conducting a sensitivity analysis using standard random-effects analyses, such as the DerSimonian-Laird estimator. 14, 15 When each end point was reanalyzed using this method, the 95% CIs for a few outcomes were narrowed whereby they did not cross unity. However, because the changes seen did not reach the level of clinical relevance, the conclusions remain unchanged.
Conclusions
In this meta-analysis of patients with persistent asthma, the use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was associated with a lower risk of asthma exacerbations. Evidence for patients aged 4 to 11 years was limited.  Risk of bias: The overall pattern within the 7 risk of bias domains was considered along with how much the individual study contributed to the overall analysis sample size.  Consistency: Consistency refers to the degree of similarity in the direction of effects (do all studies show the same effect, e.g. all superior or all null) and the magnitude of effect (the degree to which point estimates are similar) across studies within an evidence base. The magnitude of effect is often evaluated quantitatively using test for the presence (e.g., Cochran's Q tes) or the magnitude of heterogeneit (e.g., I
2 statistic).  Directness: Directness of evidence expresses how closely available evidence measures an outcome of interest, both in the directness of the outcome and the comparison. This represents a slingle link between an intervention and the outcome. Comparisons are considered direct when the studies compare interventions specifically with each other.  Precision: Precision is the degree of certainty surrounding an estimate of effect with respect to an outcome.
A precise body of evidence should enable decisionmakers to draw conclusions about whether one treatment is superior, inferior, or equivalent to another. For continuous outcomes, we used the minimally important difference (where available) for each outcome and whether confidence intervals crossed that threshold. For dichotomous outcomes, we used a relative risk increase or reuction of 0.25 from the point estimate. If the confidence interval crossed these thresholds, the outcome was comparison/outcome was considered imprecise.  Publication bias: Publication bias occurs when a decision is made to publish or report research findings based on their direction or magnitude of effect. Visual evaluations of funnel plots and tests for plot asymmetry were considered. Significant evaluations and tests were deemed to have positive publication bias.
Using evaluations of the 5 domains above, strength of evidence for each comparison and outcome was defined as:
 High: We are very confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has few or no deficiencies. We believe that the findings are stable, i.e., another study would not change the conclusions.  Moderate: We are moderately confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has some deficiencies. We believe the findings are likely to be stable, but some doubt remains.  Low: We have limited confidence that the estimate of effect lies close to the true effect for this outcome.
The body of evidence has major or numerous deficiencies (or both). We believe that additional evidence is needed before concluding either that the findings are stable or that the estimate of effect is close to the true effect.  Insufficient: We have no evidence, we are unable to estimate an effect, or we have no confidence in the estimate of the effect for this outcome. No evidence is available of the body of evidence has unacceptable deficiencies, precluding reaching a conclusion.
The strength of evidence was downgraded when one or more of the five domains above were noted. Box sizes are proportional to study weight (box center positioned at point estimate of effect). Horizontal lines indicate 95% CIs. The I 2 value indicates the percentage of variability across the pooled estimates attributable to statistical heterogeneity (range 0-100%), and the p-value is a test of heterogeneity across all studies (p value < 0.10 indicates likely variation across pooled estimates related to statistical heterogeneity). The term "Events" refers to the number of participants in each arm who experienced an event.
Abbreviations: CI, confidence interval; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; OR, odds ratio; SMART, Single Maintenance And Reliever Therapy.
